Mabqi is joigning the ESMO Congress in Paris

We are pleased to announce our participation in the ESMO Targeted Anticancer Therapies Congress, taking place in Paris, France, from March 16–18.
This leading oncology congress focuses on novel targets, precision medicines, and early clinical development, bringing together key stakeholders across translational and clinical oncology.

During the Antibody-based therapies poster session (Monday, March 16, 5.30-6.30 PM), Baptiste Gouyou and Tristan Mangeat, scientists will showcase the latest preclinical results of our lead candidates:

• Tumor-specific anti-CD30 ADC limits sCD30 sink effects and improves in vivo efficacy compared to brentuximab vedotin (poster #8P)
  This work highlights a next-generation antibody–drug conjugate engineered to address soluble CD30-mediated sink effects, resulting in improved in vivo antitumor activity.

• Development of a tumor-specific anti-TRPV6 therapeutic antibody in metastatic prostate cancer indication (poster #9P)
  This poster presents the development of a first-in-class therapeutic antibody targeting TRPV6 with tumor specificity, supporting its potential in metastatic prostate cancer.

We look forward to highlighting our new developments and engaging with oncology professionals during ESMO TAT 2026.

Feel free to connect beforehand to book a slot with our scientists here!